Q3 2024 Personalis Inc Earnings Call Transcript
Key Points
- Personalis Inc (PSNL) achieved a 41% year-over-year revenue increase in Q3 2024, reaching $25.7 million.
- The company's BioPharma business grew by 96% year-over-year, driven by strong demand for tumor profiling and MRD products.
- Personalis Inc (PSNL) raised approximately $62 million in capital, ending Q3 with $143.7 million in cash, extending their cash runway into the first half of 2027.
- The company has a strong partnership with Tempus, which has over 200 representatives promoting their products, contributing to a 68% increase in clinical tests delivered in Q3.
- Personalis Inc (PSNL) is making significant progress in clinical evidence and reimbursement efforts, with multiple studies submitted for peer review and potential reimbursement for two indications expected in 2025.
- Personalis Inc (PSNL) reported a net loss of $39.1 million in Q3 2024, including a $26 million non-cash expense related to warrant exercises.
- The company expects a sequential decline in revenue for Q4 2024, with guidance set at $15 to $16 million, primarily due to reduced revenue from Moderna and Natera.
- Gross margins are impacted by unreimbursed clinical test costs, with potential headwinds of 15 to 18 percentage points expected in 2025.
- The company's reliance on a few key partnerships, such as with Moderna, poses a risk if these relationships do not continue to generate substantial revenue.
- Personalis Inc (PSNL) is still awaiting reimbursement for their MRD tests, which could impact future revenue growth if delayed.
Good afternoon, everyone and welcome to personnel. Third quarter, 2024 earnings conference call.
All participants. I listen-only mode the question and answer session will follow the formal presentation.
If anyone should require operator assistance during the conference, please press the star key and then zero on your telephone keypad.
Please note that this event is being recorded.
I'd now like to turn the conference over to Caroline corner. Please go ahead ma'am.
Thank you operator. Welcome to personal analysis. Third quarter 2024 earnings call. Joining today's call are Chris Hall, Chief Executive Officer and President Aaron Tsha Bana, chief financial and Chief Operating Officer and Rich Chan, Chief Medical Officer and EVP R&D. All statements made on this call that do not relate to matters of historical facts should be considered forward-looking statements within the meanings of the US security laws. For example, any statements regarding trends and expectations
| Access to All Earning Calls and Stock Analysis | |
| 30-Year Financial on one screen | |
| All-in-one Stock Screener with unlimited filters | |
| Customizable Stock Dashboard | |
| Real Time Insider Trading Transactions | |
| 8,000+ Institutional investors’ 13F holdings | |
| Powerful Excel Add-in and Google sheets Add-on | |
| All data downloadable | |
| Quick customer support | |
| And much more... |
Trustpilot
We'd love to learn more about your experiences on GuruFocus.com and how we can improve!
Take Survey
